What is Apremilast/Apremilast?

Apremilast/Apremilast is an innovative oral drug mainly used to treat psoriasis and related inflammatory diseases. Apremilast inhibits the activity of PDE-4 and increases the level of intracellular cyclic adenosine monophosphate (cAMP), thereby regulating the production and release of various inflammatory mediators, thereby exerting a powerful anti-inflammatory effect. This mechanism of action gives Apremilast a significant advantage in the treatment of psoriasis.

Apremilast has been widely used in the treatment of psoriasis, especially in patients with moderate to severe plaque psoriasis. It can effectively reduce the severity of skin lesions and reduce the appearance of symptoms such as erythema and scale, thereby significantly improving the patient's appearance and quality of life. In addition, for patients with psoriatic arthritis, Apremilast can also help reduce joint symptoms and improve joint function.

Apremilast has a good safety profile and most patients tolerate treatment with the drug. Although some minor adverse reactions may occur during use, such as diarrhea, nausea, etc., most of these reactions are short-lived and tolerable. Long-term follow-up data shows that Apremilast has no obvious serious adverse reactions such as liver and kidney toxicity and bone marrow suppression, so patients can use it with confidence.

Apremilast is relatively convenient to use and does not require complex pre-medication screening or frequent monitoring during medication. Patients only need to follow the doctor's instructions and take the medication orally on time and in the right amount. This convenient way of taking medication improves treatment compliance and convenience, allowing patients to better adhere to treatment and achieve better results.